Invokana, a type 2 diabetes drug manufactured by Johnson & Johnson’s Janssen Pharmaceutical, has been linked to ketoacidosis, a potentially fatal condition involving elevated blood acid levels. Farxiga, Jardiance and other “SGLT2 inhibitors” have also been associated with the dangerous complication. The Food & Drug Administration has warned current patients to watch for symptoms and is considering further regulatory action.
As a result, patients who suffered ketoacidosis after being prescribed Invokana or other SGLT2 inhibitors are considering legal action.
Banville Law is following this developing litigation closely. On this page, you’ll find breaking Invokana news and essential legal information.